Clinical trials: MASLD, active
Coronary Artery Disease, Arterial Stiffness, Blood Pressure
Expanded Studies on the SCAPIS Stockholm Reexamination Cohort
The Swedish CArdioPulmonary bioImage Study (SCAPIS) is a unique, large-scale national research initiative involving 30,000 randomly selected individuals aged 50-64, recruited between 2014 and 2018.
- Conditions
- Coronary Artery Disease, Arterial Stiffness, Blood Pressure, AORTIC VALVE DISEASES, Mitral Valve Stenosis and/or Insufficiency
- Trial name
- SCAPIS-ReEx (NCT07476703)
- Testing
- Coronary computer tomography (CCTA), Echocardiograhy and aortic ultrasound, Liver elastography
- Where
- Sweden
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Danderyd Hospital
Obesity & Overweight, Diabetes Mellitus, Type 2
Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks
This is a nationwide, multi-center, long-term follow-up study of overweight and obese adults in China. The study aims to recruit approximately 26,000 participants across 39 hospitals to better understand how body weight affects…
- Conditions
- Obesity & Overweight, Diabetes Mellitus, Type 2, Hypertension, Non-alcoholic Fatty Liver Disease (MASLD)
- Trial name
- NCT07884903
- Testing
- No intervention; observational assessment only
- Where
- China
- Volunteers
- 25,974 people
- Sponsor
- Shanxi Bethune Hospital
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Prevalence and Clinical Significance of Hematological Abnormalities in Patients With Clinically Diagnosed Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Case-Control Study
this study aims to investigate the prevalence of hematological abnormalities among patients with clinically diagnosed MASLD, evaluate their clinical correlates, and examine their association with non-invasive fibrosis scores.
- Trial name
- MASLD (NCT07872059)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assiut University
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study
The goal of this observational study is to understand how metabolic dysfunction-associated steatotic liver disease (MASLD) changes over time in individuals with type 2 diabetes who previously participated in the EPSONIP study.
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis, Advanced Fibrosis, Sarcopenia
- Trial name
- EPSOMIP2 (NCT07312136)
- Where
- Sweden
- Volunteers
- 317 people
- Sponsor
- Linkoeping University
MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
AGED Diagnostics Clinical Validation Study
Validation of Blood-Based Tests for the Diagnosis of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Liver Fibrosis: This study aims to validate two investigational blood tests developed by AGED Diagnostics for the…
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), Fibrosis and Cirrhosis of Liver, MetALD
- Trial name
- NCT07867574
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Active Genomes Expressed Diagnostics, Corp
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Cardiovascular Disease (CVD)
Cardiovascular Risk Assessment and Coronary Calcium Score in Thai MASLD Patients
Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in Thailand and is strongly linked to metabolic risk factors such as obesity, diabetes, hypertension, and dyslipidemia.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Cardiovascular Disease (CVD), Coronary Artery Calcification
- Trial name
- MASLD-CAC (NCT07865936)
- Where
- Thailand
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Watcharasak Chotiyaputta
Diabete Mellitus, MASLD
RESET-INSPIRE Study: Insulin Sensitivity & Population Intervention With Real-time Evaluation Using CGM
The RESET-INSPIRE study is designed to investigate individual variability in glucose response and insulin sensitivity, a key mechanism underlying metabolic-associated steatotic liver disease (MASLD) and cardiometabolic disorders.
- Trial name
- RESET-INSPIRE (NCT07861191)
- Where
- Singapore
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- National University Health System, Singapore
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections
Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With HIV
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, is an increasingly recognized comorbidity in people living with human immunodeficiency virus (HIV).
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections, Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis
- Trial name
- NCT07861594
- Volunteers
- 250 people
- Sponsor
- Assiut University
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called metabolic dysfunction-associated steatohepatitis (MASH).
- Trial name
- NCT07854782
- Testing
- ALN-CIDEB
- Volunteers
- 1,500 people
- Sponsor
- Regeneron Pharmaceuticals
Obesity, Type 2 Diabetes (T2D)
A Retrospective Real-World Cohort Study
The primary objectives are to determine the prevalence and overlap of major cardiometabolic diseases, identify multimorbidity clusters, and characterize demographic, clinical, laboratory, and treatment patterns across the cohort…
- Conditions
- Obesity, Type 2 Diabetes (T2D), Prediabetes, Cardiovascular Disease (CVD)
- Trial name
- SCALA-TK-CM (NCT07781371)
- Testing
- No treatment given
- Where
- Denmark
- Volunteers
- 100,000 people
- Sponsor
- Novo Nordisk A/S
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty…
- Trial name
- NCT07527910
- Testing
- ALN-PNP, Tirzepatide
- Where
- 9 sites in United States
- Volunteers
- 204 people
- Sponsor
- Regeneron Pharmaceuticals
Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH)
A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment
This study aims to evaluate the pharmacokinetic effects of a single dose of HRS-4729 injection in participants with mild, moderate, and severe renal impairment, with 8 participants enrolled in each renal impairment group and 8…
- Conditions
- Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH), Type 2 Diabetes Mellitus
- Trial name
- NCT07807059
- Testing
- HRS-4729
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
T2DM (Type 2 Diabetes Mellitus), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Duodenal pulsENDO for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease
This study is designed to evaluate the efficacy, safety, and mechanisms of pulsENDO procedure in patients with T2DM and its effect on MASLD.
- Conditions
- T2DM (Type 2 Diabetes Mellitus), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Syndrome (MetS)
- Trial name
- DRESS-1 (NCT07390422)
- Testing
- pulsENDO treatment
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
MASLD, Obesity
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes…
- Trial name
- NCT06934642
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of New Mexico
Fatty Liver, NAFLD - Non-Alcoholic Fatty Liver Disease
Detecting Liver Fibrosis in Patients At-risk
The project will establish a research cohort (called STELIR; STEatotisk Liver-risk In Rogaland) based on a biobank with an associated health register.
- Conditions
- Fatty Liver, NAFLD - Non-Alcoholic Fatty Liver Disease, Nash, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
- Trial name
- STELIR (NCT07775638)
- Testing
- Routine study procedure
- Where
- Norway
- Volunteers
- 1,200 people
- Sponsor
- Helse Stavanger HF
HCC, MASLD
Accumulation of Lipid Droplets as an Underlying Cause of the Progression of Fatty Liver Disease to Liver Cancer
Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the leading cause of chronic liver disease, accounting for an increasing burden of cirrhosis, hepatocellular carcinoma (HCC), and related mortality…
- Trial name
- NCT07775716
- Testing
- Comprehensive Genomic and Transcriptomic Profiling, Patient-Derived Human Liver Organoid (HLO) Development, AI-Driven Digital Pathology (HistoIndex)
- Where
- Italy
- Volunteers
- 35,500 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Healthy, Fatty Liver
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
A generic screening study to establish structural and/or functional baselines of specific organs.
- Conditions
- Healthy, Fatty Liver, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- MASLD (NCT04873258)
- Testing
- Bioimpedence Vector Analysis
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Richmond Research Institute
Acute Lung Injury(ALI), Liver Cirrhosis
Digital Early Warning System for Acute Lung Injury in Liver Surgery
This study aims to develop an explainable machine learning model that takes into account the characteristics of cardiopulmonary interactions.
- Conditions
- Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD
- Trial name
- NCT07070362
- Where
- 4 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)
The goal of this prospective, multicenter, open-label, blinded end-point pragmatic study is to evaluate an artificial intelligence (AI)-augmented echocardiography screening approach for early detection of metabolic dysfunction…
- Trial name
- SCOUT Echo-AI (NCT07216859)
- Testing
- AI-Enabled Identification (EchoNet-Liver)
- Where
- 6 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Kaiser Permanente
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis
Isocaloric Navy-Bean Substitution in Adults With MASLD
This study is a 24-week randomized crossover feasibility trial evaluating an isocaloric navy-bean dietary substitution in 40 adults with metabolic dysfunction-associated steatotic liver disease (MASLD) and intermediate-stage…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Trial name
- BEAN-MASLD (NCT07730853)
- Testing
- Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Icahn School of Medicine at Mount Sinai